Install
Clinical Trials (Phases I–IV)
Design, endpoints, enrollment, interim reads, and post‑market surveillance.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Clinical Trials (Phases I–IV)
The Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Size in the 7MM is projected to grow with a significant CAGR by 2036, estimates DelveInsight
1+ hour, 48+ min ago (79+ words) The Chronic Inflammatory Demyelinating Polyneuropathy openPR.com The Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Size in the 7MM is projected to grow with a significant CAGR by 2036, estimates DelveInsight Press release from: DelveInsight Business Research LLP Chronic Inflammatory Demyelinating Polyneuropathy Market…...
Astellas Doses First Patient in Phase 3 Study of setidegrasib in Previously Treated KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer
5+ hour, 41+ min ago (115+ words) Sep 23, 2026, 19:30 ET - Study evaluates novel, investigational KRAS G12D-targeted protein degrader setidegrasib versus docetaxel in previously treated patients with advanced NSCLC - - Milestone marks second Phase 3 study of setidegrasib initiated within six months - For more information on the Phase 3 study of setidegrasib…...
New Data Highlights the Dosing Flexibility of Low-Sodium Oxybate
13+ hour, 19+ min ago (148+ words) Sep 23, 2026 | Idiopathic Hypersomnia, Narcolepsy, Prescription Drugs | 0 | In the post-hoc analysis of the DUET study, researchers evaluated three cohorts of patients who completed a stable-dose period: idiopathic hypersomnia, narcolepsy with optimized doses of 9 g or less per night, and narcolepsy with…...
Vistagen’s fasedienol shows positive data in open-label extension for social anxiety disorder
22+ hour, 18+ min ago (388+ words) The Clinical Trial Vanguard Vistagen’s fasedienol shows positive data in open-label extension for social anxiety disorder The open-label extension of Vistagen’s PALISADE-4 Phase 3 trial is producing something the randomized portion did not: positive data for fasedienol in the acute treatment of…...
Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances to Dose Expansion
23+ hour, 25+ min ago (454+ words) BioSpace Rise Therapeutics Completes Dose Escalation in R-5780 Phase 1 Cancer Trial, Advances to Dose Expansion ROCKVILLE, Md., Sept. 22, 2026 /PRNewswire/ -- Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, today announced that it has completed the dose escalation portion of its…...
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
1+ day, 11+ hour ago (698+ words) BioSpace Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas Newly allowed claims provide LP‑284 patent protection into 2042 for the treatment of mantle cell lymphoma and double-hit lymphoma, two blood cancers with high-unmet-needs…...
Asthma Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Therapeutics Landscape
2+ day, 8+ hour ago (63+ words) Asthma Clinical Trial Pipeline: DelveInsight Highlights Major openPR.com Asthma Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Therapeutics Landscape Press release from: ABNewswire Permanent link to this press release: You can edit or…...
OS Therapies Aligns With FDA on Phase 3 Design, Accepts MHRA's Project Orbis Invitation for OST-HER2
2+ day, 10+ hour ago (675+ words) BioBuzz OS Therapies Aligns With FDA on Phase 3 Design, Accepts MHRA’s Project Orbis Invitation for OST-HER2 OS Therapies, Inc., a Rockville, Maryland- and New York-based clinical-stage oncology company, announced on September 17, 2026 that it has achieved incremental alignment with the FDA…...
B-Cell Non-Hodgkin Lymphoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight
2+ day, 8+ hour ago (59+ words) B-Cell Non-Hodgkin Lymphoma Clinical Trial Pipeline: Emerging openPR.com B-Cell Non-Hodgkin Lymphoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight Press release from: ABNewswire Permanent link to this press release: You can edit or delete…...
Cue’s anti-IgE antibody CUE-221 meets Phase II endpoints in chronic urticaria
2+ day, 16+ hour ago (648+ words) AllSci CUE-221 (UB-221), a dual-mechanism anti-IgE monoclonal antibody being developed by Boston-based Cue Biopharma (Nasdaq: CUE), met both its primary and key secondary endpoints in a Phase II study in chronic spontaneous urticaria (CSU), according to topline results released September…...